New hope for hard-to-treat cancers? drug combo trial begins
NCT ID NCT07563738
First seen May 10, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study tests a new drug called ODM-212 combined with other anti-cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it works. About 229 adults with limited treatment options are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
Contact
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.